HOMER的奥德赛:COVID-19大流行期间阿片类药物使用障碍的比较效果研究》(The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder during the COVID-19 Pandemic)。
Linda Zittleman, John M Westfall, Benjamin Sofie, Cory Lutgen, Douglas Fernald, Tristen L Hall, Camille J Hochheimer, Melanie Murphy, Maret Felzien, L Miriam Dickinson, Brian K Manning, Joseph LeMaster, Donald E Nease
{"title":"HOMER的奥德赛:COVID-19大流行期间阿片类药物使用障碍的比较效果研究》(The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder during the COVID-19 Pandemic)。","authors":"Linda Zittleman, John M Westfall, Benjamin Sofie, Cory Lutgen, Douglas Fernald, Tristen L Hall, Camille J Hochheimer, Melanie Murphy, Maret Felzien, L Miriam Dickinson, Brian K Manning, Joseph LeMaster, Donald E Nease","doi":"10.1370/afm.3149","DOIUrl":null,"url":null,"abstract":"<p><p>The usual challenges of conducting primary care research, including randomized trials, have been exacerbated, and new ones identified, during the COVID-19 pandemic. HOMER (Home versus Office for Medication Enhanced Recovery; subsequently, Comparing Home, Office, and Telehealth Induction for Medication Enhanced Recovery) is a pragmatic, comparative-effectiveness research trial that aims to answer a key question from patients and clinicians: What is the best setting in which to start treatment with buprenorphine for opioid use disorder for this patient at this time? In this article, we describe the difficult journey to find the answer. The HOMER study began as a randomized trial comparing treatment outcomes in patients starting treatment with buprenorphine via induction at home (unobserved) vs in the office (observed, synchronous). The study aimed to enroll 1,000 participants from 100 diverse primary care practices associated with the State Networks of Colorado Ambulatory Practices and Partners and the American Academy of Family Physicians National Research Network. The research team faced unexpected challenges related to the COVID-19 pandemic and dramatic changes in the opioid epidemic. These challenges required changes to the study design, protocol, recruitment intensity, and funding conversations, as well as patience. As this is a participatory research study, we sought, documented, and responded to practice and patient requests for adaptations. Changes included adding a third study arm using telehealth induction (observed via telephone or video, synchronous) and switching to a comprehensive cohort design to answer meaningful patient-centered research questions. Using a narrative approach based on the Greek myth of Homer, we describe here the challenges and adaptations that have provided the opportunity for HOMER to thrive and find the way home. These clinical trial strategies may apply to other studies faced with similar cultural and extreme circumstances.</p>","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":"22 5","pages":"444-450"},"PeriodicalIF":4.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419717/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic.\",\"authors\":\"Linda Zittleman, John M Westfall, Benjamin Sofie, Cory Lutgen, Douglas Fernald, Tristen L Hall, Camille J Hochheimer, Melanie Murphy, Maret Felzien, L Miriam Dickinson, Brian K Manning, Joseph LeMaster, Donald E Nease\",\"doi\":\"10.1370/afm.3149\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The usual challenges of conducting primary care research, including randomized trials, have been exacerbated, and new ones identified, during the COVID-19 pandemic. HOMER (Home versus Office for Medication Enhanced Recovery; subsequently, Comparing Home, Office, and Telehealth Induction for Medication Enhanced Recovery) is a pragmatic, comparative-effectiveness research trial that aims to answer a key question from patients and clinicians: What is the best setting in which to start treatment with buprenorphine for opioid use disorder for this patient at this time? In this article, we describe the difficult journey to find the answer. The HOMER study began as a randomized trial comparing treatment outcomes in patients starting treatment with buprenorphine via induction at home (unobserved) vs in the office (observed, synchronous). The study aimed to enroll 1,000 participants from 100 diverse primary care practices associated with the State Networks of Colorado Ambulatory Practices and Partners and the American Academy of Family Physicians National Research Network. The research team faced unexpected challenges related to the COVID-19 pandemic and dramatic changes in the opioid epidemic. These challenges required changes to the study design, protocol, recruitment intensity, and funding conversations, as well as patience. As this is a participatory research study, we sought, documented, and responded to practice and patient requests for adaptations. Changes included adding a third study arm using telehealth induction (observed via telephone or video, synchronous) and switching to a comprehensive cohort design to answer meaningful patient-centered research questions. Using a narrative approach based on the Greek myth of Homer, we describe here the challenges and adaptations that have provided the opportunity for HOMER to thrive and find the way home. These clinical trial strategies may apply to other studies faced with similar cultural and extreme circumstances.</p>\",\"PeriodicalId\":50973,\"journal\":{\"name\":\"Annals of Family Medicine\",\"volume\":\"22 5\",\"pages\":\"444-450\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419717/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Family Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1370/afm.3149\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Family Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1370/afm.3149","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
在 COVID-19 大流行期间,开展初级保健研究(包括随机试验)通常面临的挑战更加严峻,而且还发现了新的挑战。HOMER("在家与办公室用药促进康复";随后是 "比较在家、办公室和远程医疗诱导用药促进康复")是一项务实的比较效果研究试验,旨在回答患者和临床医生提出的一个关键问题:此时对这名患者来说,开始使用丁丙诺啡治疗阿片类药物使用障碍的最佳环境是什么?在本文中,我们将介绍寻找答案的艰难历程。HOMER 研究最初是一项随机试验,比较患者在家中(非观察)与在诊室(观察、同步)通过诱导开始丁丙诺啡治疗的疗效。该研究的目标是招募来自与科罗拉多州非住院医疗实践和合作伙伴网络以及美国家庭医生学会国家研究网络相关的 100 家不同初级保健实践的 1000 名参与者。研究团队面临着与 COVID-19 大流行和阿片类药物流行的巨大变化有关的意想不到的挑战。这些挑战要求我们改变研究设计、方案、招募强度和资金对话,同时也要求我们保持耐心。由于这是一项参与性研究,我们寻求、记录并回应了实践和患者提出的调整要求。这些改变包括增加第三组研究,使用远程医疗诱导(通过电话或视频进行同步观察),以及改用综合队列设计来回答以患者为中心的有意义的研究问题。我们以希腊神话《荷马史诗》为蓝本,采用叙事的方法,在此描述了 HOMER 所面临的挑战和做出的调整,这些调整为 HOMER 的发展提供了机会,并让 HOMER 找到了回家的路。这些临床试验策略可能适用于面临类似文化和极端环境的其他研究。
The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic.
The usual challenges of conducting primary care research, including randomized trials, have been exacerbated, and new ones identified, during the COVID-19 pandemic. HOMER (Home versus Office for Medication Enhanced Recovery; subsequently, Comparing Home, Office, and Telehealth Induction for Medication Enhanced Recovery) is a pragmatic, comparative-effectiveness research trial that aims to answer a key question from patients and clinicians: What is the best setting in which to start treatment with buprenorphine for opioid use disorder for this patient at this time? In this article, we describe the difficult journey to find the answer. The HOMER study began as a randomized trial comparing treatment outcomes in patients starting treatment with buprenorphine via induction at home (unobserved) vs in the office (observed, synchronous). The study aimed to enroll 1,000 participants from 100 diverse primary care practices associated with the State Networks of Colorado Ambulatory Practices and Partners and the American Academy of Family Physicians National Research Network. The research team faced unexpected challenges related to the COVID-19 pandemic and dramatic changes in the opioid epidemic. These challenges required changes to the study design, protocol, recruitment intensity, and funding conversations, as well as patience. As this is a participatory research study, we sought, documented, and responded to practice and patient requests for adaptations. Changes included adding a third study arm using telehealth induction (observed via telephone or video, synchronous) and switching to a comprehensive cohort design to answer meaningful patient-centered research questions. Using a narrative approach based on the Greek myth of Homer, we describe here the challenges and adaptations that have provided the opportunity for HOMER to thrive and find the way home. These clinical trial strategies may apply to other studies faced with similar cultural and extreme circumstances.
期刊介绍:
The Annals of Family Medicine is a peer-reviewed research journal to meet the needs of scientists, practitioners, policymakers, and the patients and communities they serve.